The National Institute of Health and Care Excellence (NICE) has issued final guidance that does not recommend the use of Imnovid (pomalidomide) as a treatment for myeloma patients after third or subsequent relapse. This is based on its opinion that the clinical benefits of the drug do not justify its high costs. Currently, patients in England and Wales can still access Imnovid via the Cancer Drugs Fund.


Read full article